Neoadjuvant Chemotherapy As a Potential Treatment Option in Colon Cancer

2019 ◽  
Keyword(s):  
Colon Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Treatment Option ◽  
Potential Treatment

Pregnancy and depression: Exploring a new potential treatment option

2009 ◽  
Vol 11 (6) ◽  
pp. 443-446 ◽  
Author(s):  
Deborah R. Kim ◽  
Juan Gonzalez ◽  
John P. O’Reardon
Keyword(s):  
Treatment Option ◽  
Potential Treatment

Neoadjuvant chemotherapy in locally advanced colon cancer: a systematic review and meta-analysis

2021 ◽  
Author(s):  
Rathin Gosavi ◽  
Clemente Chia ◽  
Michael Michael ◽  
Alexander G. Heriot ◽  
Satish K. Warrier ◽  
...  
Keyword(s):  
Systematic Review ◽  
Colon Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Meta Analysis ◽  
Locally Advanced ◽  
Advanced Colon Cancer

scholarly journals In vitro and in vivo studies on stilbene analogs as potential treatment agents for colon cancer

2010 ◽  
Vol 45 (9) ◽  
pp. 3702-3708 ◽  
Author(s):  
Shiby Paul ◽  
Cassia S. Mizuno ◽  
Hong Jin Lee ◽  
Xi Zheng ◽  
Sarah Chajkowisk ◽  
...  
Keyword(s):  
Colon Cancer ◽  
In Vivo Studies ◽  
Potential Treatment ◽  
Stilbene Analogs

scholarly journals Cannabis, a potential treatment option in pediatric IBD? Still a long way to go

2019 ◽  
Vol 12 (4) ◽  
pp. 355-361 ◽  
Author(s):  
Nienke Halbmeijer ◽  
Michael Groeneweg ◽  
Lissy De Ridder
Keyword(s):  
Treatment Option ◽  
Potential Treatment ◽  
Pediatric Ibd

scholarly journals How and why SGLT2 inhibitors should be explored as potential treatment option in diabetic retinopathy: clinical concept and methodology

2019 ◽  
Vol 10 ◽  
pp. 204201881989188 ◽  
Author(s):  
Marcus May ◽  
Theodor Framke ◽  
Bernd Junker ◽  
Carsten Framme ◽  
Amelie Pielen* ◽  
...  
Keyword(s):  
Treatment Option ◽  
Microvascular Complications ◽  
Treatment Options ◽  
Sglt2 Inhibitors ◽  
Diabetic Microangiopathy ◽  
Potential Treatment ◽  
Treatment And Prevention ◽  
Clinical Complications ◽  
Sodium Glucose Cotransporter ◽  
Increased Risk

Patients suffering from type 2 diabetes are at an increased risk of developing classical microvascular complications such as retinopathy, neuropathy, and nephropathy, which represent a significant health burden. Tight control of blood glucose, blood pressure, and serum cholesterol reduce the risk of microvascular complications but effective pharmacologically targeted treatment options for the treatment and prevention of diabetic microangiopathy are still lacking. Pharmacological inhibition of sodium glucose cotransporter 2 (SGLT2) might have the potential to directly protect against microvascular complications and could represent a potential treatment option. Randomized controlled clinical proof of concept trials are needed to investigate a potential central role of SGLT2 inhibitors in the prevention of diabetic microangiopathy and its classical clinical complications of retinopathy, neuropathy, and nephropathy.

scholarly journals Neoadjuvant Chemotherapy for Locally Advanced T4 Colon Cancer: A Nationwide Propensity-Score Matched Cohort Analysis

2019 ◽  
Vol 37 (4) ◽  
pp. 292-301 ◽  
Author(s):  
Jan-Marie de Gooyer ◽  
Marlies G. Verstegen ◽  
Jorine ’t Lam-Boer ◽  
Sandra A. Radema ◽  
Rob H.A. Verhoeven ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Propensity Score ◽  
Cohort Analysis ◽  
Locally Advanced ◽  
Group Versus ◽  
Control Group ◽  
Complication Rates ◽  
Term Survival ◽  
T4 Colon Cancer

Introduction: Neoadjuvant chemotherapy (CT) for locally advanced colon cancer (LACC) could potentially lead to tumor shrinkage, eradication of micrometastases, and prevention of tumor cell shedding during surgery. This retrospective study investigates the surgical and oncological outcomes of preoperative CT for LACC. Methods: Using the Netherlands Cancer Registry, data of patients with stage II or III colon cancer, diagnosed between 2008 and 2016 was collected. A propensity score matching (PSM; 1:2) was performed and compared patients with clinical tumor (cT) 4 colon cancer who were treated with neoadjuvant CT to patients with cT4 colon cancer treated with adjuvant CT (Fig. 1). Results: A total of 192 patients treated with neoadjuvant CT were compared to 1,954 patients that received adjuvant CT. After PSM, 149 patients in the neoadjuvant group were compared to 298 patients in the control group. No significant differences were found in baseline characteristics after PSM. After neoadjuvant CT, a significant response was observed in 13 (9%) patients with 5 (4%) patients showing a complete response. Complete resection margins (R0) were achieved in 77% in the neoadjuvant group versus 86% in the adjuvant treated group (p = 0.037). Significantly less tumor positive lymph nodes were found in the neoadjuvant group (median 0 vs. 2, p < 0.001). Major complication rates and 5-year overall survival did not differ between both groups (67–65%, p = 0.87). Conclusion: Neoadjuvant CT seems safe and feasible with similar long-term survival compared to patients who are treated with adjuvant CT.

scholarly journals Targeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option

2019 ◽  
Vol 30 ◽  
pp. v791-v792 ◽  
Author(s):  
S.V. Liu ◽  
M. Duruisseaux ◽  
K. Tolba ◽  
E. Branden ◽  
Y. Goto ◽  
...  
Keyword(s):  
Treatment Option ◽  
Potential Treatment ◽  
Multiple Tumour
Sign in / Sign up

Export Citation Format

Share Document